Inozyme Pharma Inc (NASDAQ:INZY)’s traded shares stood at 0.41 million during the last session, with the company’s beta value hitting 1.28. At the close of trading, the stock’s price was $1.45, to imply a decrease of -3.33% or -$0.05 in intraday trading. The INZY share’s 52-week high remains $7.80, putting it -437.93% down since that peak but still an impressive 14.48% since price per share fell to its 52-week low of $1.24. The company has a valuation of $93.15M, with an average of 0.78 million shares in intraday trading volume over the past 10 days and average of 781.52K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Inozyme Pharma Inc (INZY), translating to a mean rating of 1.11. Of 6 analyst(s) looking at the stock, 0 analyst(s) give INZY a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.37.
Inozyme Pharma Inc (NASDAQ:INZY) trade information
After registering a -3.33% downside in the last session, Inozyme Pharma Inc (INZY) has traded red over the past five days. The 5-day price performance for the stock is 0.69%, and -48.58% over 30 days. With these gigs, the year-to-date price performance is -47.65%. Short interest in Inozyme Pharma Inc (NASDAQ:INZY) saw shorts transact 3.85 million shares and set a 5.41 days time to cover.
The extremes give us $16 and $16 for target low and target high price respectively. As such, INZY has been trading -1003.45% off suggested target high and -1003.45% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -35.73% for the past 5-year period. While 2025 is set for a -16.59% return in earnings, projections for the next 5 years are at -5.45% annually.
INZY Dividends
Inozyme Pharma Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Inozyme Pharma Inc (NASDAQ:INZY)’s Major holders
Inozyme Pharma Inc insiders hold 0.62% of total outstanding shares, with institutional holders owning 98.87% of the shares at 99.49% float percentage. In total, 98.87% institutions holds shares in the company, led by ADAGE CAPITAL PARTNERS GP, L.L.C.. As of 2024-06-30, the company held over 5.73 million shares (or 9.2742% of shares), all amounting to roughly $25.55 million.
The next major institution holding the largest number of shares is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC with 4.49 million shares, or about 7.2765% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $20.05 million.
We also have Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Fidelity Select Portfolios – Biotechnology as the top two Mutual Funds with the largest holdings of the Inozyme Pharma Inc (INZY) shares. Going by data provided on Sep 30, 2024 , Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund holds roughly 4.13 shares. This is just over 6.44% of the total shares, with a market valuation of $5.99 million. Data from the same date shows that the other fund manager holds a little less at 1.9, or 2.96% of the shares, all valued at about 2.76 million.
